Article
IL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study.
Brain, behavior, and immunity - 1 Aug 2024
Ho Ming-Fen, Zhang Cheng, Cohan James S, Tuncturk Mustafa, Heider Robin M, Coombes Brandon J, Biernacka Joanna, Moon Irene, Skime Michelle, Ho Ada M, Ngo Quyen, Skillon Cedric, Croarkin Paul E, Oesterle Tyler S, Karpyak Victor M, Li Hu, Weinshilboum Richard M
Abstract excerpt
Acamprosate is a Food and Drug Administration (FDA) approved medication for the treatment of alcohol use disorder (AUD). However, only a subset of patients achieves optimal treatment outcomes. Currently, no biological measures are utilized to predict response to acamprosate treatment. We applied our established pharmaco-omics informed genomics strategy to identify potential biomarkers associated with acamprosate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
